$4995 | Single User
$7495 | Global License

FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US)

Published by FirstWord Pharma: 20 Apr 2015 | 220 | In Stock

Introduction

Introduction


What environmental market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to availability to reimbursement factors, FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US) provides insights that can help develop, shape and refine your brand strategies. Also Available is FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5). To purchase both and receive a free US/EU5 Comparison report, contact FirstWord.


Based on data gained from proprietary analytics, gain visibility into why physicians are prescribing, or not, certain drugs to treat T2DM. This information allows you to act strategically, drive market share gains and improve competitiveness for your brand.


Puchase Reasons


Get Answers to Key Questions


  • How does product pricing, availability and reimbursement affect a physician’s decision to prescribe one product over another?

  • What T2DM drug treatments are gaining share and which ones are losing share due to these barriers?

  • In the T2DM market, what percentage of prescriptions are influenced by barriers, what are the barriers experienced and the volume of prescriptions these barriers represent?

  • Insight and Analysis Provided


  • AstraZeneca

  • Byetta (exenatide)

  • Onglyza (saxagliptin)

  • Farxiga (dapagliflozin)

  • Johnson & Johnson

  • Invokana (canagliflozin)

  • Merck & Co.

  • Januvia (sitagliptin)

  • Novo Nordisk

  • Victoza (liraglutide)

  • Levemir (Insulin detemir)

  • Sanofi

  • Lantus (Insulin glargine)

  • Key Issues Explored


  • The amount of share your brand gains and loses due to specific market barriers.

  • The user mix for your brand, plus doctors who are not current users but would consider using it.

  • The percentage of prescriptions influenced by barriers, the barriers experienced and the volume of scripts these barriers represent.

  • Methodology


    Sample Distribution


  • A mixed total of 150: 66 endocrinologists and 84 general practitioners in France, Italy, Spain, Germany, UK

  • Interviewing Methodology


  • Data collected via a 10-minute questionnaire.

  • Screening Criteria





    About FirstWord Reports


    FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.


  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

  • Learn more at www.firstwordgroup.com.

    Table of Contents
    for FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US)

    • 1.Current user base and overall market barrier impact

      1.1.Current usage and consideration

      1.2.Overall market barrier impact

      1.3.Losses and gains due to barriers

      1.4.Barrier effect score

      2.Brand specific barrier impact

      2.1.Why do I lose or gain share?

      2.2.Who gets my share?

      2.3.Whose share do I get?

      3.Appendix

      3.1.Physician profile

      3.2.Barrier effect score summary

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    220 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5)
    IntroductionWhat market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to a...
    20 Apr 2015 by FirstWord Pharma USD $4,995 More Info
    FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (EU5)
    IntroductionFirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (US) provides ...
    01 Mar 2015 by FirstWord Pharma USD $4,995 More Info
    FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (US)
    IntroductionFirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (EU5) provides...
    01 Mar 2015 by FirstWord Pharma USD $4,995 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US) | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • Allied Market Research
    • CBR Pharma
    • Current Partnering
    • Firstword
    • Global Data
    • Global Markets Direct
    • ICD Research
    • Infinti Research Technavio
    • Marketline
    • Markets and Markets
    • Micro Markets Monitor
    • MP Advisors
    • Venture Planning Group
    • GMR Data